Insider trading activity remains a key metric for assessing internal confidence within publicly traded companies. Recent filings reveal that Crystal Adam, who serves as the President of Research & Development at Tango Therapeutics, Inc. (NASDAQ:TNGX), executed substantial stock sales on June 1, 2026. These transactions involved disposing of common stock valued near $617,571, and they followed an earlier period where Ms. Adam had acquired shares through the exercise of vested options.
Specifically, Ms. Adam disposed of a total holding of 27,000 shares of Tango Therapeutics common stock. The sales were structured across two distinct tranches. The first block comprised 6,140 shares and was sold at a weighted average price of $22.252 per share; individual transaction prices within this group ranged from $21.58 to $22.57. Separately, the second block included 20,860 shares, which were sold at a weighted average price of $23.0558 per share. The pricing for this larger segment varied between $22.60 and $23.42.
The market context surrounding these sales is noteworthy. At the time of reporting, TNGX stock was trading at $21.47, which represented a significant 563% return over the preceding year. Furthermore, an analysis conducted by InvestingPro suggested that the current valuation levels might be elevated, assigning an estimated Fair Value to the stock at $18.12.
Preceding Acquisition Details
Before liquidating these holdings, Ms. Adam had first acquired 27,000 common shares through the exercise of her stock options. This acquisition was completed at a price point of $5.20 per share, totaling $140,400.
This specific option exercise is connected to a larger grant that has a vesting schedule spanning four years. The initial milestone required 25% of the grant's shares to vest on February 27, 2024. The remaining portion of the grant is scheduled for distribution through 36 equal monthly payments thereafter. Importantly, the expiration date set for this option is March 1, 2033.
Regulatory Framework and Current Holdings
It is crucial to note that all transactions documented, encompassing both the initial acquisition of shares and the subsequent sales, were carried out in adherence to a Rule 10b5-1 trading plan. Ms. Adam formally adopted this plan on October 27, 2025. Following these recent activities, her direct holdings consist of 115,743 shares of Tango Therapeutics common stock. In addition to her outright shares, she retains 341,040 derivative shares in the form of stock options.
Analyst Coverage and Company Developments
In parallel with the insider trading report, Tango Therapeutics has been subject to varied analyst commentary and corporate updates. The company's strategic direction has prompted several rating adjustments. Piper Sandler downgraded the stock from Overweight to Neutral, citing a shift in Tango’s approach concerning pancreatic ductal adenocarcinoma. Despite this downgrade, the firm raised its price target to $24.00, suggesting underlying optimism regarding the company's trajectory.
Similarly, Mizuho adjusted its outlook by raising its price target to $30 while maintaining an Outperform rating. This adjustment followed the increase in the probability of success for Tango’s first-line pancreatic ductal adenocarcinoma program, which was raised to 75%. Meanwhile, Jefferies issued a downgrade, moving the rating from Buy to Hold, though they increased their price target to $27.00$. The firm highlighted TNGX's progress in developing combination therapies targeting pancreatic and certain lung cancers.
Further corporate news included Tango Therapeutics finalizing a separation agreement with its former CFO, Daniella Beckman, following her departure. Stifel provided the highest price target among the mentioned firms, raising it to $40$, citing potential within TNGX's drug combination strategy for pancreatic cancer. These varied analyses underscore continuous interest and divergent professional perspectives regarding the company's future operational capacity.
Market data snapshots show that at a closing price of $21.27$ (down 0.20 or -0.93% after hours), the stock was trading, with historical charts providing context up to five years and maximum ranges for analysis.